Engineered multifunctional metal–phenolic nanocoatings for label-free capture and "self-release" of heterogeneous circulating tumor cells. Issue 40 (15th September 2021)

• Record Type: Journal Article
• Authors: Liu, Yiling; Wang, Xiaoshan; Zhou, Yuwei; Yang, Guang; Hou, Jianwen; Zhou, Shaobing
• Is Part Of: Nanoscale. Volume 13:Issue 40(2021)
• Page Start: 16923
• Page End: 16931
• Publication Date: 2021-09-15
• Subjects: Nanoscience -- Periodicals; Nanotechnology -- Periodicals; 620.505
• DOI: 10.1039/d1nr04112f
• Languages: English
• ISSNs: 2040-3364

Abstract

Abstract : Heterogeneous CTCs in whole blood can be efficiently captured and self-released by multifunctional metal–phenolic networks without using any labeling molecules and additional interventions. Abstract : Immunomagnetic beads have been widely explored as an important analytical tool for the rapid and sensitive detection of circulating tumor cells (CTCs). However, their clinical application is seriously hindered by the tedious preparation procedures and heterogeneous nature of CTCs. To this end, a designed multifunctional platform named Fe3 O4 @TA/Cu II superparamagnetic nanoparticles (SPMNPs) is expected to have the following features: (i) the formation of a tannic acid–copper (ii ) ion (TA/Cu II ) coating which could be accomplished by a one-step method is very simple; (ii) the TA/Cu II coating shows high affinity for heterogeneous CTCs and good resistance to nonspecific adhesion of blood cells; (iii) "self-release" of the captured cells could be achieved as the TA/Cu II coating gradually degrades in the cell culture environment without any additional interventions. Therefore, the resulting Fe3 O4 @TA/Cu II SPMNPs could capture various CTCs (MCF-7, HepG2 and HeLa cells) with different expression levels of the epithelial cell adhesion molecule (EpCAM). And the capture efficiency and cell purity can reach 88% and 87%, respectively. In addition, 68% of the captured cells are self-released after 6 h of incubation and most of the released cells show high cell proliferation activity. In particular, Fe3 O4 @TA/Cu II SPMNPs can successfully detect 1–13 CTCs from 1 mL of blood of 14 patients with 6 types of cancers. Hence, we expect that the as-prepared Fe3 O4 @TA/Cu II SPMNPs with simple, efficient, and universal yet cost-efficient characteristics could act as a promising analytical tool for clinical CTC detection.